101. Acute Regulation of Lipolysis by CB1 Cannabinoid Receptor Antagonism.
- Author
-
Wilbur, Kelly, Briere, Daniel A., Keding, Stacy J., Michael, M. D., and Sloop, Kyle W.
- Subjects
LIPOLYSIS ,CANNABINOIDS ,INSULIN ,DIABETES ,TRIGLYCERIDES ,ADIPOSE tissues ,ADENYLATE cyclase - Abstract
Rimonabant (SR-141716A) clinical trials demonstrate that antagonism of the CB1 cannabinoid receptor can result in better glucose control as indicated by a reduction in HbA[sub 1c] levels and an improvement in insulin sensitization in treated patients. These effects may be mediated in part through regulation of white adipose tissue lipolysis, the catabolic process whereby triglyceride stores are hydrolyzed to fatty acids and glycerol. In adipose tissue, catecholamine binding to β-adrenergic receptors activates adenylate cyclase through a G[sub s]-coupled mechanism, thereby increasing intracellular cAMP levels. Subsequent activation of protein kinase A by cAMP results in phosphorylation and activation of hormone-sensitive lipase, the rate-limiting enzyme in lipolysis. To explore the effect of cannabinoid modulation of adenlyate cyclase activity, an HTRF (Homogenous Time-Resolved Fluorescence) assay was established to measure the concentration of intracellular cAMP. The CB1 receptor agonist, R(+)-WIN55, 212-2, inhibited forskolin-stimulated cAMP production in CHO cells expressing the CB1 receptor, and SR-141716A blocked this effect in a dose-dependent manner. Consistent with a G[sub i]-coupling mechanism, pertussis toxin attenuated the CB1 receptor agonist-mediated inhibition but not the stimulation of cAMP production. Similar to the in vitro results, CB1 receptor agonist treatment of ob/ob mice acutely inhibited fasting-induced levels of plasma FFAs, an effect that was blocked by SR-141716A administration. Together, these data provide additional evidence that CB1 receptor antagonism regulates adipose tissue lipid metabolism. [ABSTRACT FROM AUTHOR]
- Published
- 2007